Evidence map›Paper›PMID 39199324›Full record

ArticleBiomolecules2024

Loss-of-Imprinting of HM13 Leads to Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Floris Voorthuijzen, Cedric Stroobandt, Wim Van Criekinge, Tine Goovaerts, Tim De Meyer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Floris VoorthuijzenDepartment Data Analysis and Mathematical Modelling, BIOBIX Lab of Bioinformatics and Computational Genomics, Ghent University, Coupure Links 653, B9000 Ghent, Belgium.ORCID 0009-0001-1339-4841
Cedric StroobandtDepartment Data Analysis and Mathematical Modelling, BIOBIX Lab of Bioinformatics and Computational Genomics, Ghent University, Coupure Links 653, B9000 Ghent, Belgium.
Wim Van CriekingeDepartment Data Analysis and Mathematical Modelling, BIOBIX Lab of Bioinformatics and Computational Genomics, Ghent University, Coupure Links 653, B9000 Ghent, Belgium.
Tine GoovaertsDepartment Data Analysis and Mathematical Modelling, BIOBIX Lab of Bioinformatics and Computational Genomics, Ghent University, Coupure Links 653, B9000 Ghent, Belgium.
Tim De MeyerDepartment Data Analysis and Mathematical Modelling, BIOBIX Lab of Bioinformatics and Computational Genomics, Ghent University, Coupure Links 653, B9000 Ghent, Belgium.ORCID 0000-0003-2994-9693

Funding

Ghent University BOF.24Y.2019.0020.01Ghent University BOF.DOC.2019.0036.02Research Foundation - Flanders 1128021N
6 · The paper itself

Abstract

Genomic imprinting refers to the epigenetic silencing of one of both alleles in a parent-of-origin-specific manner, particularly in genes regulating growth and development. Impaired genomic imprinting leading to the activation of the silenced allele, also called canonical loss-of-imprinting (LOI), is considered an early factor in oncogenesis. As LOI studies in clear cell renal cell carcinoma (ccRCC) are limited to

Indexed as

Carcinoma, Renal CellGenomic ImprintingKidney NeoplasmsAgedFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMaleMiddle AgedPrognosisInsulin-Like Growth Factor IICRYBB2P1H13HM13KIRC/ccRCCloss-of-imprinting (LOI)

Identifiers

PMID39199324
PMCPMC11352930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.